ABCB1 and non-small cell lung carcinoma: Thus, the aim of this work was to perform a further extensive characterization of the ABCB1 inhibitory action of this new probucol diester derivative, AIF-1, and its potential to enhance the antitumor effect of doxorubicin using in vitro and in vivo models of non-small cell lung cancer (NSCLC).